iShares JPMorgan USD Emerging Markets Bond ETF vs Novo Nordisk A/S — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $94.83, while Novo Nordisk A/S trades at $45.84 (market cap $207.31B). The key difference: Novo Nordisk A/S pays a 3.76% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals.
| EMB | NVO | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $63.98 |
52-Week Low | $92.95 | $35.29 |
Market Cap | — | $207.31B |
Enterprise Value | — | $222.02B |
Dividend Yield | — | 3.76% |
Signals from Pluang's Aura AI — not financial advice
EMB, the iShares J.P. Morgan USD Emerging Markets Bond ETF, trades at $95.24, up 0.31% over 24 hours. Technical indicators are mixed, with a neutral overall signal and bearish moving averages. Recent dividend distributions provide income, but key financial ratios are unavailable. News sentiment highlights yield-driven returns amid emerging market sovereign risks.
Outlook hinges on income from its 5.1% yield, with limited price upside expected. Risks include emerging market defaults and Federal Reserve policy shifts. Analysts rate it a hold, emphasizing diversification benefits but cautioning on macro triggers.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →